All In Biotech

Drug Trial Radar · NCT07585383

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single and Multiple Doses of KR23248 Capsules in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

May 19, 2026

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
May 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China. It will enroll male and female participants aged 18 years to 45 years.

Conditions

  • Schizophrenia

Interventions

  • KR23248Drug

    Participants will recieve a single oral dose of KR23248

  • Matching PlaceboDrug

    Participants will recieve placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), serious adverse events(SAEs), drug-related AEs, and AEs leading to study withdrawalTime frame: SAD:Day 1 to Day14 MAD:Day1 to Day28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.